Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:57 AM
Ignite Modification Date:
2025-12-26 @ 10:57 AM
NCT ID:
NCT02064608
Eligibility Criteria:
Inclusion Criteria:
* Men aged 18 years old or older
* ECOG performance status of 0 or 1
* Clinical diagnosis of Intermediate (one or more of stage T2, or PSA \>10ng/mL, or Gleason score of at least 7) or High Risk Prostate Cancer (one or more of stage T2c, or PSA \>20ng/mL, or Gleason score of at least 8)
* Patient suitable for radical prostatectomy, following discussion at specialist MDT and subsequent review by surgical team
* Willing to use barrier contraceptive method, e.g. condom \& spermicide
* Adequate bone marrow reserve or organ function (as specified in the study protocol)
* Normal chest radiograph and oxygen saturations, OR normal CT thorax
Exclusion Criteria:
* Contraindication to AZD2014 (as specified in the study protocol)
* Patients who have experienced any of the following procedures in the past 12 months: coronary artery bypass graft; angioplasty; vascular stent; myocardial infarction; angina pectoris; congestive heart failure (New York Heart Association grade of 2 or above); ventricular arrhythmias requiring continuous therapy; supraventricular arrhythmias including atrial fibrillation, which are uncontrolled; haemorrhagic or thrombotic stroke including transient ischaemic attacks or any other CNS bleeding.
* Previous chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents and/or investigational agents within 28 days of starting study treatment.
* Major surgery within 4 weeks prior to study entry (excluding placement of vascular access), or minor surgery within 2 weeks of entry into the study
* Potent or moderate inhibitors and inducers of CYP2C8 if taken within the stated wash-out period: Gemfibrozil, trimethoprim, glitazones, montelukast, deferasirox and quercetin (1-week minimum wash out period)
* Any haematopoietic growth factors, e.g. G-CSF, GM-CSF, within 4 weeks prior to receiving study drug
* As judged by the Investigator, any evidence of severe or uncontrolled systemic disease (as specified in the study protocol)
* Abnormal ECHO or MUGA at baseline
* Mean resting QTc of 470msec or above (as per local reading)
* Concomitant medications known to prolong QT interval, or with factors that increase the risk of QTc prolongation, or risk of arrythmic events (examples specified in study protocol). History of Torsades de Pointes.
* Patients with Diabetes Type I or uncontrolled Type II as judged by the investigator
* Judgement by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.
* Unable to provide informed consent
Healthy Volunteers:
False
Sex:
MALE
Minimum Age:
18 Years
Study:
NCT02064608
Study Brief:
Protocol Section:
NCT02064608